circulating thyroxine, thyroid-stimulating hormone, and hypothyroid status and the risk of prostate cancer循环甲状腺素、促甲状腺激素和甲状腺地位和患前列腺癌的风险.pdfVIP

Circulating Thyroxine, Thyroid-Stimulating Hormone, and Hypothyroid Status and the Risk of Prostate Cancer 1 1 2 2 3 Alison M. Mondul *, Stephanie J. Weinstein , Tracey Bosworth , Alan T. Remaley , Jarmo Virtamo , Demetrius Albanes1 1 Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Department of Health and Human Services, Bethesda, Maryland, United States of America, 2 Laboratory Medicine Department, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, United States of America, 3 Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland Abstract Background: Thyroid hormones may influence risk of cancer through their role in cell differentiation, growth, and metabolism. One study of circulating thyroid hormones supports this hypothesis with respect to prostate cancer. We undertook a prospective analysis of thyroid hormones and prostate cancer risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. Methods: Within the ATBC Study, a randomized controlled trial of a-tocopherol and b-carotene supplements and cancer incidence in male smokers, 402 prostate cancer cases were sampled. Controls were matched 2:1 to cases on age and date of blood collection. Odds ratios (OR) and 95% confidence intervals (CI) of prostate cancer were estimated for quintiles of serum total and free thyroxine (T4), thyroid-stimulating hormone (TSH), thyroid-binding globulin (TBG), and by categories of thyroid status. Results: Men with serum higher TSH had a decreased risk of prostate cancer compared to men with lower TSH (Q